

# NutropinAq® Information for Patients



## NutropinAq® Pen

for use with

## NutropinAq®

[somatropin, recombinant DNA origin, *Escherichia coli*]

### Your doctor has prescribed NutropinAq for you.

Take this information sheet and your prescription to your pharmacist, either at your hospital pharmacy or your local community pharmacy.

### Patients starting on NutropinAq

If you are a **new patient** to NutropinAq your pharmacist will order a NutropinAq New Patient Pack for you. A New Patient Pack provides you with additional information and resources.

The New Patient Pack contains:

- NutropinAq Pen
- Information Pack: How to Inject guide & Consumer Medicine Information
- Box of 100 Needles
- Sharps Container

### Patients already on NutropinAq

If you are a patient who is already on NutropinAq, it is unlikely that you will need a new box of needles and sharps container each time you pick up NutropinAq from your pharmacy. If you require a new box of needles or sharps container please let your pharmacist know.

- If your sharps container is full, ensure you return it to your local pharmacy for safe disposal.

# NutropinAq® Ordering Information for Pharmacists

NutropinAq (Somatotropin - recombinant human growth hormone) can only be ordered through Clifford Hallam Healthcare (CH2), with a CH2 account or via credit card. Note: new accounts can take up to 7 working days to be opened.



[www.ch2.net.au](http://www.ch2.net.au)



1300 720 274 (CH2 customer service)

## New NutropinAq patients require a NutropinAq New Patient Pack which contains:

- NutropinAq 10mg/2ml cartridge, NutropinAq Pen, NutropinAq Injection Guide, Consumer Medicine Information (CMI) leaflet, needles and a sharps container
- If a patient requires more than one Nutropin 10mg/2ml cartridge; order one Nutropin NEW Adult/Paed Pack and extra NutropinAq cartridges (1756791) as required.

## For existing patients, NutropinAq can be ordered:

- Separately for patients that don't require needles and sharps containers with every NutropinAq 10mg/2ml prescription refill (NutropinAq 10mg/2mL cartridge only)
- In packs containing NutropinAq 10mg/2ml, needles and a sharps container (NutropinAq Existing Adult/Paed Pack)

Packs are available with either adult or paediatric sized needles.

## NutropinAq ordering details

Code	Description	Cartridge (10mg/2mL)	Needles (100 pc)	Sharps container	NutropinAq Pen	CMI	Patient guide
1756791	NutropinAq 10mg ONLY	✓	-	-	-	-	-
2461581	NutropinAq 10mg EXISTING Adult Pack*	✓	5mm	✓	-	-	-
2459230	NutropinAq 10mg EXISTING Paediatric Pack*	✓	8mm	✓	-	-	-
2461599	NutropinAq 10mg EXISTING Alternative Pack*	✓	4mm	✓	-	-	-
2461610	NutropinAq 10mg NEW Adult Pack	✓	5mm	✓	✓	✓	✓
2461601	NutropinAq 10mg NEW Paediatric Pack	✓	8mm	✓	✓	✓	✓
2016971	NutropinAq Replacement PEN	If a replacement pen is required, please contact Ipsen Medical Information on 1800 317 033. Ipsen will contact CH2 to approve the release of a replacement pen from reserved stock.					

\*Existing patients will not need an EXISTING Adult/ Paediatric Pack (containing needles and sharps containers) every time they pick up their script; NutropinAq cartridges can be ordered separately using code 1756791 (NutropinAq 10mg/2mL only)

If you have any medical related queries regarding NutropinAq or NutropinAq Pen please contact Ipsen Medical Information on 1800 317 033.

**PBS Information:** This product is listed on the PBS as a Section 100 item.  
Refer to PBS Schedule for full authority information

Before prescribing please refer to the full Product Information, which is available from Ipsen Medical Information. Ph: 1800 317 033 or from <http://www.medicines.org.au/files/ispnut10.pdf>

**NutropinAq®:** Somatropin (recombinant human growth hormone) **Indications:** Growth failure due to inadequate endogenous growth hormone secretion in children; Growth failure associated with Turner syndrome; Growth failure associated with chronic renal insufficiency up to the time of renal transplantation in prepubertal children; Adults with severe growth hormone deficiency. **Dose:** Growth failure in children due to inadequate growth hormone secretion: 0.025–0.035 mg/kg bodyweight daily; Growth failure associated with Turner syndrome: up to 0.05 mg/kg bodyweight daily; Growth failure associated with chronic renal insufficiency: up to 0.05 mg/kg bodyweight daily; Growth hormone deficiency in adults: low initial doses of 0.15–0.3 mg daily. The dose should be adjusted stepwise, controlled by serum IGF-1 values. The recommended final dose seldom exceeds 1.0 mg/day in adults. In older or overweight patients, lower doses may be necessary. Women may require higher doses than men, with men showing an increasing IGF-1 sensitivity over time. In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal. **Administration:** Daily subcutaneous injection in the upper arm, abdomen or thigh. Alternate the site of injection. Do not inject if the solution is cloudy. NutropinAq is only intended for use in one individual and only with the NutropinAq Pen (refer to separate pen dosing instructions). **Contraindications:** Hypersensitivity to ingredients; growth promotion in patients with closed epiphyses; active tumour – intracranial lesions must be inactive and antitumour therapy completed prior to starting growth hormone therapy – discontinue treatment if any evidence of tumour growth; initiation of treatment in patients with acute critical illness due to complications after open-heart or abdominal surgery, multiple accidental traumas or patients who have acute respiratory failure. **Precautions:** Maximum recommended daily dose should not be exceeded; establish etiology in adults with growth hormone deficiency; previous malignant disease; pre-existing tumours or GH deficiency secondary to intracranial lesion; Prader-Willi syndrome in paediatric patients unless growth hormone deficiency diagnosed; continuation of treatment in patients with acute critical illness due to complications after open-heart or abdominal surgery, multiple accidental traumas or patients who have acute respiratory failure; GH failure secondary to chronic renal insufficiency; higher incidence of slipped capital femoral epiphyses in paediatric patients with advanced renal osteodystrophy or endocrine disorders – investigate complaints of knee or hip pain or onset of a limp; monitor for possible signs of scoliosis; monitor for glucose intolerance; monitor patients with glucose sensitivity or diabetes closely and adjust insulin doses if required; not indicated in diabetic patients with retinopathy; intracranial hypertension, hypothyroidism and leukaemia have been reported; increased risk of pancreatitis in children; terminate treatment after renal transplantation; concomitant treatment with glucocorticoids. **Drug Interactions:** Drugs metabolised by CYP450 liver enzymes; potential inhibition of 11 $\beta$ HSD-1 and reduced serum cortisol concentrations; unmasking of undiagnosed secondary hypoadrenalism; may render low glucocorticoid replacement doses ineffective; possible glucocorticoid dose increases in hypoadrenalism; oral oestrogen therapy. Pregnancy category B2: NutropinAq should be discontinued if pregnancy occurs. Lactation: Excretion in milk unknown. **Effect on driving/using machinery:** No known effects. **Adverse Events:** Common to very common (reported in clinical trials): hypothyroidism, glucose tolerance impaired, headache, hypertonia, arthralgia, myalgia, peripheral oedema, oedema, asthenia, injection site reaction, drug specific antibody present. **Indication specific adverse events:** (common to very common): paediatric patients – CNS neoplasm, menorrhagia, renal failure, peritonitis, osteonecrosis, blood creatinine increase; adult patients – paraesthesia, hyperglycaemia, hyperlipidaemia, insomnia, synovial disorder, arthrosis, muscular weakness, back pain, breast pain, gynaecomastia – see full PI. **Storage:** 2°C–8°C

For further information, please contact Ipsen Pty Ltd: T (03) 8544 8100 F (03) 9562 5152 E [info@ipsen.com.au](mailto:info@ipsen.com.au)  
Ipsen Pty Ltd Level 2, Building 4, Brandon Office Park, 540 Springvale Road, Glen Waverley, VIC 3150 Australia  
ABN 47 095 036 909. NutropinAq® is a registered trade mark. Date of preparation: October 2020. NUT-AU-000032.

**NutropinAq®**  
[somatropin, recombinant  
DNA origin, *Escherichia coli*]

 **IPSEN**  
Innovation for patient care



To access a video on  
“How To Use NutropinAq  
with the NutropinAq Pen”:

Visit:

[www.nutropin.com.au](http://www.nutropin.com.au)



and enter the last 4 digits of  
the barcode on your NutropinAq  
box in the Patient Login section

OR

Scan this QR code



This information is for your  
familiarisation only. If you  
have any questions or require  
advice, please seek the  
advice of your healthcare  
professional.



If you have any medical related queries regarding NutropinAq or NutropinAq Pen please  
contact Ipsen Medical Information on 1800 317 033.

Ipsen Pty Ltd: T (03) 8544 8100 F (03) 9562 5152 E [info@ipsen.com.au](mailto:info@ipsen.com.au) Ipsen Pty Ltd Level 2, Building 4, Brandon Office  
Park, 540 Springvale Road, Glen Waverley, VIC 3150 Australia ABN 47 095 036 909. NutropinAq<sup>®</sup> is a registered trade mark.  
Date of preparation: October 2020. NUT-AU-000032.

**NutropinAq<sup>®</sup>**  
[somatropin, recombinant  
DNA origin, *Escherichia coli*]

**IPSEN**  
Innovation for patient care